Vivimed Labs.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Drugs
  • ISIN: INE526G01021
  • NSEID: VIVIMEDLAB
  • BSEID: 532660
INR
6.44
-0.1 (-1.53%)
BSENSE

May 25

BSE+NSE Vol: 43.95 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationUpcoming Result: Vivimed Labs. will declare its result soon on 28 May 2026
stock-recommendationMojo Score Change: Vivimed Labs. has changed its score on 12 May 2026. Click here to unlock latest mojo score!
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

43.95 k (-64.02%) Volume

Shareholding (Mar 2026)

FII

1.64%

Held by 5 FIIs

DII

0.12%

Held by 0 DIIs

Promoter

7.57%

When is the next results date for Vivimed Labs Ltd?

10-Mar-2026

The next results date for Vivimed Labs Ltd is 13 March 2026.

The next results date for Vivimed Labs Ltd is scheduled for 13 March 2026.

View full answer

Should I buy, sell or hold Vivimed Labs Ltd?

12-May-2026

Why is Vivimed Labs Ltd falling/rising?

24-May-2026

As of 24-May, Vivimed Labs Ltd's stock price is at 6.50, down 1.52%, and has significantly underperformed the Sensex. The company faces high debt, negative earnings, and a substantial year-to-date decline of 63.13%, indicating a bearish trend and increased risk.

As of 24-May, Vivimed Labs Ltd's stock price is falling, currently at 6.50, reflecting a change of -0.1, or -1.52%. The stock has underperformed compared to the Sensex, which has increased by 0.24% over the past week. Over the last month, Vivimed Labs has seen a decline of 6.07%, while the Sensex decreased by a lesser 3.95%. Year-to-date, the stock has plummeted by 63.13%, significantly worse than the Sensex's decline of 11.51%.<BR><BR>The company's performance today indicates it has underperformed its sector by 0.47%. Additionally, Vivimed Labs is trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which suggests a bearish trend. Although there has been a notable increase in investor participation, with delivery volume rising by 161.18% against the 5-day average, this has not translated into a positive price movement.<BR><BR>Several negative factors contribute to the stock's decline. The company has a high debt-to-equity ratio of 9.51 times, indicating significant leverage and a weak long-term fundamental strength. Its ability to service this debt is low, as evidenced by a negative debt-to-EBITDA ratio of -2.02 times. Furthermore, the company has reported losses, leading to negative return on equity (ROE) and a negative EBITDA of Rs. -11.15 crore. Over the past year, profits have fallen dramatically by 386%, and the stock is considered risky compared to its historical valuations. These factors collectively explain the ongoing decline in Vivimed Labs Ltd's stock price.

View full answer
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

With HIgh Debt (Debt-Equity Ratio at 9.51 times)- the company has a Weak Long Term Fundamental Strength

  • Low ability to service debt as the company has a high Debt to EBITDA ratio of -2.02 times
  • The company has reported losses. Due to this company has reported negative ROE
2

Flat results in Dec 25

3

Risky - Negative EBITDA

stock-summaryMojo Parameters

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

stock-summary
Industry

Pharmaceuticals & Drugs

stock-summary
Market cap

INR 54 Cr (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

34

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

9.51

stock-summary
Return on Equity

-833.41%

stock-summary
Price to Book

1.37

Revenue and Profits:
Net Sales:
16 Cr
(Quarterly Results - Dec 2025)
Net Profit:
-17 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-16.36%
0%
-16.36%
6 Months
0%
0%
0.0%
1 Year
0%
0%
0.0%
2 Years
0%
0%
0.0%
3 Years
0%
0%
0.0%
4 Years
-51.76%
0%
-51.76%
5 Years
-78.89%
0%
-78.89%

Latest dividend: 0.4 per share ex-dividend date: Sep-19-2018

Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions

News

Announcements stock-summary

Vivimed Labs Limited - Clarification - Financial Results

09-Dec-2019 | Source : NSE

Vivimed Labs Limitedbs Limited for the quarter ended 30-Sep-2019 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Vivimed Labs Limited - Outcome of Board Meeting

15-Nov-2019 | Source : NSE

Vivimed Labs Limited has informed the Exchange regarding Board meeting held on November 14, 2019.

Vivimed Labs Limited - Updates

22-Oct-2019 | Source : NSE

Vivimed Labs Limited has informed the Exchange regarding 'Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the Quarter ended September 30, 2019'.

Corporate Actions stock-summary

stock-summary
BOARD MEETING

28 May 2026

stock-summary
DIVIDEND

Vivimed Labs Ltd has declared 20% dividend, ex-date: 19 Sep 18

stock-summary
SPLITS

Vivimed Labs Ltd has announced 2:10 stock split, ex-date: 06 Apr 16

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available

stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
-53.40%
EBIT Growth (5y)
-421.22%
EBIT to Interest (avg)
-1.77
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
9.51
Sales to Capital Employed (avg)
0.80
Tax Ratio
0.64%
Dividend Payout Ratio
0
Pledged Shares
15.18%
Institutional Holding
1.76%
ROCE (avg)
-0.76%
ROE (avg)
0

Valuation key factors

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
34
Price to Book Value
1.40
EV to EBIT
-13.43
EV to EBITDA
-38.55
EV to Capital Employed
1.04
EV to Sales
3.96
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-71.39%
ROE (Latest)
-833.41%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
Bearish
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2026stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Non Institution

Pledged Promoter Holdings

15.1806

Mutual Funds

Held by 0 Schemes

FIIs

Held by 5 FIIs (1.64%)

Promoter with highest holding

Varalwar Sandeep (2.81%)

Highest Public shareholder

Kitara Piin 1102 (9.37%)

Individual Investors Holdings

68.75%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "11.63",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-11.22",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Interest",
          "val1": "0.94",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "-16.57",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-96.47%",
          "val2": "NA%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Consolidated) - Sep'22",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Sep 2022 is -21.15% vs -78.03% in Sep 2021",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": " Growth in half year ended Sep 2022 is -72.57% vs -3,185.90% in Sep 2021",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'22",
        "Sep'21",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "94.33",
          "val2": "119.63",
          "chgp": "-21.15%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-17.88",
          "val2": "0.31",
          "chgp": "-5,867.74%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "18.17",
          "val2": "18.12",
          "chgp": "0.28%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-44.23",
          "val2": "-25.63",
          "chgp": "-72.57%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-18.95%",
          "val2": "0.26%",
          "chgp": "-19.21%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Consolidated) - Dec'22",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in nine months ended Dec 2022 is -14.81% vs -78.58% in Dec 2021",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in nine months ended Dec 2022 is -26.83% vs 2.03% in Dec 2021",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'22",
        "Dec'21",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "150.07",
          "val2": "176.15",
          "chgp": "-14.81%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-23.01",
          "val2": "-6.98",
          "chgp": "-229.66%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "27.39",
          "val2": "29.70",
          "chgp": "-7.78%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-62.54",
          "val2": "-49.31",
          "chgp": "-26.83%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-15.33%",
          "val2": "-3.96%",
          "chgp": "-11.37%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is -37.86% vs -21.15% in Mar 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is 90.27% vs -385.63% in Mar 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "116.27",
          "val2": "187.10",
          "chgp": "-37.86%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-13.05",
          "val2": "-187.30",
          "chgp": "93.03%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "2.95",
          "val2": "35.90",
          "chgp": "-91.78%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-31.96",
          "val2": "-328.53",
          "chgp": "90.27%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-11.22%",
          "val2": "-100.11%",
          "chgp": "88.89%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Standalone) - Dec'25 - QoQstock-summary

Dec'25
Change(%)
Net Sales
11.63
NA
NA
Operating Profit (PBDIT) excl Other Income
-11.22
NA
NA
Interest
0.94
NA
NA
Exceptional Items
0.00
NA
NA
Standalone Net Profit
-16.57
NA
NA
Operating Profit Margin (Excl OI)
-96.47%
NA%
NA
Values in Rs Cr.
Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

Half Yearly Results Snapshot (Consolidated) - Sep'22stock-summary

Sep'22
Sep'21
Change(%)
Net Sales
94.33
119.63
-21.15%
Operating Profit (PBDIT) excl Other Income
-17.88
0.31
-5,867.74%
Interest
18.17
18.12
0.28%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-44.23
-25.63
-72.57%
Operating Profit Margin (Excl OI)
-18.95%
0.26%
-19.21%
Values in Rs Cr.
Direction Arrows
Net Sales

Growth in half year ended Sep 2022 is -21.15% vs -78.03% in Sep 2021

Direction Arrows
Consolidated Net Profit

Growth in half year ended Sep 2022 is -72.57% vs -3,185.90% in Sep 2021

Nine Monthly Results Snapshot (Consolidated) - Dec'22stock-summary

Dec'22
Dec'21
Change(%)
Net Sales
150.07
176.15
-14.81%
Operating Profit (PBDIT) excl Other Income
-23.01
-6.98
-229.66%
Interest
27.39
29.70
-7.78%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-62.54
-49.31
-26.83%
Operating Profit Margin (Excl OI)
-15.33%
-3.96%
-11.37%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in nine months ended Dec 2022 is -14.81% vs -78.58% in Dec 2021

Direction Arrows
Consolidated Net Profit

YoY Growth in nine months ended Dec 2022 is -26.83% vs 2.03% in Dec 2021

Annual Results Snapshot (Consolidated) - Mar'25stock-summary

Mar'25
Mar'23
Change(%)
Net Sales
116.27
187.10
-37.86%
Operating Profit (PBDIT) excl Other Income
-13.05
-187.30
93.03%
Interest
2.95
35.90
-91.78%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-31.96
-328.53
90.27%
Operating Profit Margin (Excl OI)
-11.22%
-100.11%
88.89%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2025 is -37.86% vs -21.15% in Mar 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Mar 2025 is 90.27% vs -385.63% in Mar 2023

stock-summaryCompany CV
About Vivimed Labs Ltd stock-summary
stock-summary
Vivimed Labs Ltd
Micro Cap
Pharmaceuticals & Drugs
Vivimed Labs Ltd is engaged in manufacturing of Specialty Chemicals (mainly used in Personal Care and Cosmetic Industry), Pharmaceuticals, API's and Formulations. The company has strong presence in the areas of Health & Personal Care, Contract Research and Manufacturing. The company has four subsidiary companies, namely Creative Health Care Pvt Ltd, Vivimed Holdings Ltd (Hong Kong), Vivimed Labs Europe Ltd (UK) and Vivimed Labs USA Inc.
Company Coordinates stock-summary
Company Details
Plot No 78-A, Kolhar Industrial Area Bidar Karnataka : 585403
stock-summary
Tel: 91-8482-232045
stock-summary
yugandhar.kopparthi@vivimeslabs.com
Registrar Details
Aarthi Consultants Pvt Ltd, 1-2-285 , Domalaguda, Hyderabad